February 14, 2011 15:17 ET

Unilens Vision Reports Second Quarter Operating Results, Including 67% Increase in Diluted EPS ($0.15 vs. $0.09) on Fewer Shares Outstanding

Company's Emphasis Upon Specialty Contact Lenses Anticipates Above-Average Growth of America's Presbyopic Population

LARGO, FL--(Marketwire - February 14, 2011) - Unilens Vision Inc. (OTCBB: UVIC) (TSX-V: UVI), which develops, licenses, manufactures, distributes and markets specialty contact lenses, today reported its operating results for the second quarter and first half of FY2011.

For the three months ended December 31, 2010 (second quarter of FY2011), total revenue including royalty income declined 2.6% to approximately $2.1 million, compared with approximately $2.2 million in the three months ended December 31, 2009. Sales of the Company's specialty contact lenses declined 1.5%, while royalty income decreased 4.8%, when compared with the prior-year quarter. The Company believes that the continued impact of a soft U.S. economy upon the specialty contact lens market and new product offerings by competitors were the primary reasons for lower sales and royalty income in the second quarter of FY2011, when compared with the year-earlier quarter.

Pretax income decreased 20.6% to $519,659 in the second quarter of FY2011, compared with $654,071 in the quarter ended December 31, 2009. The reduction in pretax income was primarily attributable to lower sales and royalty income and an increase in interest expense related to the Company's loan with Regions Bank, which financed the repurchase of 48% of the Company's previously outstanding shares in January 2010; partially offset by lower administrative and sales and marketing ("SG&A") expenses.

The Company reported net income of $350,237 in the most recent quarter, a decrease of 17.7% when compared with net income of $425,308 in last year's second fiscal quarter. The Company earned $0.15 per diluted share in the second quarter of FY2011, which represented an increase of 66.7% versus earnings of $0.09 per diluted share in the second quarter of FY2010. Diluted per-share earnings were calculated on 2,369,354 common shares in the FY2011 second quarter, versus 4,557,852 diluted shares in the prior-year quarter. The 48% decrease in weighted average diluted shares outstanding resulted from the Company's repurchase of 2,188,861 outstanding shares of common stock on January 20, 2010.

"Sales of our custom soft lens category increased significantly in the second quarter as our C-Vue Advanced Toric Multifocal lenses continue to gain traction in the marketplace, almost completely offsetting declines in our disposable lens category," observed Michael Pecora, Chief Executive Officer of Unilens Vision Inc. "The C-Vue Advanced Toric Multifocal was introduced in the first quarter of Fiscal 2010 with a free trial option, and sales have increased as eye care professionals convert trial fits to revenue-generating sales. We expect a similar phenomenon over time with our recently introduced C-Vue Advanced® HydraVUE™ line of silicone hydrogel custom contact lenses for monthly replacement, which are completely customizable and feature a risk-free trial program and exceptional deliverability."

"Although sales and royalties were lower than prior-year levels in the second quarter, we are encouraged that the 1.5% decline in our specialty contact lens sales represented an improvement relative to a 9.2% decrease in the first quarter, while the 4.8% decline in royalty income was much less severe than the 14.0% first quarter decrease. Longer-term, we believe that the specialty segment of the contact lens market will benefit significantly as the presbyopic population continues to grow at a faster rate than America's population as a whole, and we have positioned our Company to benefit from such trends by providing independent practitioners with specialty contact lens options that contribute to patient retention and practice profitability," concluded Pecora.

For the six months ended December 31, 2010, net sales including royalty income decreased 7% to approximately $4.3 million, compared with approximately $4.6 million in the first half of FY2010. The decrease in revenue was primarily due to a 5.7% decline in sales of the Company's various types of specialty contact lenses and a 9.4% decline in royalty income.

Pretax income decreased 29.8% to $1,013,823 in the six months ended December 31, 2010, compared with $1,444,801 in the prior-year period. The decrease in pretax income was primarily attributable to lower sales and royalty income and an increase in interest expense related to the Company's loan with Regions Bank, partly offset by a modest reduction in SG&A expenses.

The Company reported net income of $682,086 for the first half of FY2011, a decrease of 25.8% when compared with net income of $919,396 in the corresponding period of the previous fiscal year. The Company earned $0.29 per diluted share in the first six months of FY2011, which represented an increase of 45.0% when compared with earnings of $0.20 per diluted share in the first six months of FY2010. Diluted per-share earnings were calculated on 2,369,354 common shares in the six months ended December 31, 2010, versus 4,556,969 diluted shares in the prior-year period.

The Company recently declared its 18th consecutive quarterly cash dividend, in the amount of $0.09 per share of common stock outstanding. The amount and frequency of future dividends will depend upon earnings, cash flow, and other aspects of the Company's business as determined and declared by the Board of Directors.

About Unilens Vision Inc. -- "The Independent Eye Care Professionals' Contact Lens Company"

Established in 1989, Unilens Vision Inc., through its wholly owned subsidiary Unilens Corp., USA, located in Largo, Florida and its wholly owned subsidiary Unilens Vision Sciences Inc. develops, licenses, manufactures, distributes and markets contact lenses primarily under the C-Vue® brand directly to Independent Eye Care Professionals. Additional information on the Company may be accessed on the Internet at www.unilens.com. The Company's common stock is listed on the OTC Bulletin Board under the symbol "UVIC" and on the Canadian TSX Venture Exchange under the symbol "UVI."

The information contained in this news release, other than historical information, consists of forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those described in such statements. For a discussion of certain factors that could cause actual results to differ materially from those described in the forward-looking statements, please refer to the Company's most recent filings with the SEC and the TSX Venture Exchange. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

                            UNILENS VISION INC.
                       SECOND QUARTER -- FISCAL 2011
               CONDENSED CONSOLIDATED FINANCIAL INFORMATION

(All figures in U.S. Dollars)

RESULTS OF OPERATIONS
                            Three        Three
                           Months       Months     Six Months   Six Months
                            Ended        Ended        Ended       Ended
                           December     December     December    December
                           31, 2010     31, 2009     31, 2010    31, 2009
                          ----------  -----------  -----------  ----------
  Revenues:
  Sales                   $1,393,094  $ 1,414,539  $ 2,922,668  $3,098,212
  Royalty income             715,603      751,386    1,375,809   1,519,062
                          ----------  -----------  -----------  ----------
  Total revenues           2,108,697    2,165,925    4,298,477   4,617,274
                          ----------  -----------  -----------  ----------
  Operating costs and
   expenses:
  Cost of sales              877,754      843,217    1,775,844   1,804,588
  Expenses                   641,056      672,989    1,367,875   1,376,198
                          ----------  -----------  -----------  ----------
  Total operating costs
   and expenses            1,518,810    1,516,206    3,143,719   3,180,786
                          ----------  -----------  -----------  ----------
  Income from operations     589,887      649,719    1,154,758   1,436,488
                          ----------  -----------  -----------  ----------
  Other non-operating
   items:
  Other income                   900          355        1,445         823
  Remeasurement income             -        1,288            -       1,823
  Interest (expense)
   income                    (71,128)       2,709     (142,380)      5,667
                          ----------  -----------  -----------  ----------
  Total other non-operating
   items                     (70,228)       4,352     (140,935)      8,313
                          ----------  -----------  -----------  ----------
  Income before income tax
   expense                   519,659      654,071    1,013,823   1,444,801
  Income tax expense         169,422      228,763      331,737     525,405
                          ----------  -----------  -----------  ----------
  Net income for the
   period                 $  350,237  $   425,308  $   682,086  $  919,396
                          ==========  ===========  ===========  ==========
  Net income per common
   share:
    Basic                 $     0.15  $      0.09  $      0.29  $     0.20
    Diluted               $     0.15  $      0.09  $      0.29  $     0.20
  Weighted average shares
   outstanding             2,369,354    4,557,852    2,369,354   4,556,969
                          ==========  ===========  ===========  ==========

CASH FLOWS

  Provided (used) by:
    Operating activities                           $   495,440  $1,411,655
    Investing activities                              (131,084)    239,876
    Financing activities                            (1,026,484)   (819,128)
                                                   -----------  ----------
  (Decrease) increase in cash                      $  (662,128) $  832,403
                                                   ===========  ==========

BALANCE SHEET                           June 30,     December    December
                                          2010       31, 2010    31, 2009
                                      -----------  -----------  ----------
  Cash and cash equivalents           $ 1,080,540  $   418,412  $2,262,852
  Total assets                          4,467,338    4,099,157   5,975,079
  Current liabilities                   2,519,513    2,378,192   1,181,462
  Total liabilities                     6,819,513    6,217,768   1,181,462
  Stockholders' (deficit)
   equity                             $(2,352,175) $(2,118,611) $4,793,617
                                      ===========  ===========  ==========